Health

AviWeisfogel blazes new trails with Dental Sleep Masters

During the mid-2000s, Dr. AviWeisfogel was hard at work. While building his practice, Old Bridge Dental, into one of the most prominent in Central New Jersey, Dr. Weisfogel was putting in long hours, day after day. But he still found time for his other passions, including the field of medical research.

He was always intrigued by the idea that dentists weren’t being used to their full potential as trained medical professionals. Dr. Weisfogel knew that many patients were actually far more likely to see their dentists, over any given time period, than they were to see their general physicians. This somewhat counterintuitive fact stemmed from the nature of periodontal disease.

For example, someone who wanted to put off a routine physical cholesterol screening can do so, without apparent consequence, for years or even decades. In fact, this is what a shocking number of Americans have historically done. On the other hand, someone with an abscessed molar who attempts to put off seeing a dentist for even a couple of hours will soon be introduced to a world of pain that even morphine cannot often cure. This, likewise, holds true for other dental conditions such as cavities or even chipped teeth. While the latter may not cause the patient debilitating pain, it will quickly ruin his day if his quotidian activities typically include smiling at people.

Armed with this insight, Dr. Weisfogel set out to find for which diseases the most potential marginal gain could be made by dentists intervening in the earliest stages, when the disease most treatable. Eventually, he came across sleep apnea.

Sleep apnea, Dr. Weisfogel discovered, is one of the most underdiagnosed and lethal diseases in the country. Strongly correlated with heart disease, stroke and diabetes, it causes thousands of excess death each year in the United States. Dr. Weisfogel formed a plan.

He founded Dental Sleep Masters, a company dedicated to bringing new treatment paradigms for sleep disorders, like sleep apnea, to dentists across the nation. The program has been so successful that many of the dentists who have enrolled have quit their traditional dental practices to concentrate of sleep dentistry full time to learn more: https://www.yelp.com/biz/weisfogel-avi-dds-old-bridge click here.

Dr. Shiva Gopal Vasishta: Practicing Neurologist

Dr. Shiva Gopal Vasishta’s career started shortly after he graduated from Government Medical College. Since then, he’s practiced neurology for over 40 years. He’s one of the most respected professionals in his field on the east coast. Currently, he’s practicing Neurology at Eastern Neurodiagnostic Associates in Voorhees, New Jersey.

Like all medical professionals, he completed his mandatory medical residency before getting a formal position. He worked at several facilities during his early years, learning from numerous mentors. Finally, he settled at Eastern Neurodiagnostic. He practice supports Spanish as well as English. He’s also consistently updated on the latest neurology-related therapies and treatments.

An interesting new study revealed the benefits of stem-cell transplants as a possible treatment for multiple sclerosis (MS). The study, referred to as HALT-MS, looking at the results of high-dose immunosuppressive therapy and autologous hematopoietic cell transplant (HDIT/HCT). The results were astonishing.

The study took place over a five-year period. It studied the effects of a one-time treatment on volunteering patients. The treatment involves the stem cell transplant of one’s own blood cells. If performed at the correct time, it yielded long-term remission and showed no progression of symptoms, relapse, or new brain lesions.

The new study could be the new option for MS patients. With more study results comes better conclusions. So far, the results show a significantly higher success rate than the MS drugs currently used by most patients. Over 60 percent of participants got progressively better in a shorter time frame.

The clinical patients that participated ranged from age 26 to 52. All were previously using their current MS medicine but weren’t getting better. HDIT/HCT helped nearly 70 percent of them achieve a health status higher than before the treatment.